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In Vivo Fluorescence 
Immunohistochemistry: 
Localization of Fluorescently 
Labeled Cetuximab in Squamous 
Cell Carcinomas
Esther de Boer1, 2, Jason M. Warram1, Matthew D. Tucker1, Yolanda E. Hartman1, 
Lindsay S. Moore1, Johannes S. de Jong3, Thomas K. Chung1, Melissa L. Korb1, 
Kurt R. Zinn4, Gooitzen M. van Dam5, Eben L. Rosenthal1, Ψ & Margaret S. Brandwein-
Gensler6, Ψ
Anti-EGFR (epidermal growth factor receptor) antibody based treatment strategies have been 
successfully implemented in head and neck squamous cell carcinoma (HNSCC). Unfortunately, 
predicting an accurate and reliable therapeutic response remains a challenge on a per-patient 
basis. Although significant efforts have been invested in understanding EGFR-mediated changes 
in cell signaling related to treatment efficacy, the delivery and histological localization in (peri-)
tumoral compartments of antibody-based therapeutics in human tumors is poorly understood nor 
ever made visible. In this first in-human study of a systemically administered near-infrared (NIR) 
fluorescently labeled therapeutic antibody, cetuximab-IRDye800CW (2.5 mg/m2, 25 mg/m2, and 
62.5 mg/m2), we show that by optical molecular imaging (i.e. denominated as In vivo Fluorescence 
Immunohistochemistry) we were able to evaluate localization of fluorescently labeled cetuximab. 
Clearly, optical molecular imaging with fluorescently labeled antibodies correlating morphological 
(peri-)tumoral characteristics to levels of antibody delivery, may improve treatment paradigms based 
on understanding true tumoral antibody delivery.
The application of antibody-based therapies has significantly grown in the past 15 years; it is currently 
one of the most important targeted treatment strategies for hematological and solid malignancies1. 
Recently, cancer immunotherapy was announced to be the breakthrough of the year 2013. Targeting 
specific signaling pathways or immune effector functions has a number of advantages over conventional 
cytotoxic chemotherapeutics, such as reduced systemic off target effects and more specific cell killing2. 
Furthermore, antibody-based therapies can also be rationally combined with conventional chemotherapy 
to synergistically enhance cell killing with non-overlapping toxicities3,4. The development of anti-EGFR 
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(epidermal growth factor receptor) strategies has been one of the most successful targeted therapies, 
especially for head and neck squamous cell carcinoma (HNSCC)5. Cetuximab is an FDA approved 
anti-EGFR human-murine chimeric monoclonal antibody (mAb) that is currently used in combination 
with radiotherapy in the treatment of HNSCC, or as a single agent in patients with recurrent/metastatic 
disease for whom prior platinum-based therapy has failed6.
However, only 10–13% of patients with HNSCC are expected to benefit from EGFR inhibitors 
due to occurrence of reactivation downstream signaling despite the presence of the EGFR inhibitor, 
and predicting a patient response in terms of complete, partial or no (pathological) response remains 
challenging7. Appropriate patient selection would limit the considerable costs and significant mor-
bidity associated with unnecessary delivery of antibody based therapeutics, and thus overtreatment 
without the target of choice being present. EGFR inhibitors block ligand-binding, abrogating activa-
tion of downstream tumor-promoting pathways including apoptosis evasion (PI3K-Akt), proliferation 
(Ras-Raf-MEK-MAPK), and transcription (STAT3)8. Constitutive activation of STAT3 is considered 
the predominant promoter of EGFR inhibitor resistance9. However interrogation of these pathways in 
human disease has not led to reliable prediction of patients likely to respond to therapy. Although there 
have been substantial efforts to evaluate relationships between various molecular markers (such as levels 
of EGFR and angiogenesis) and clinical outcome by using diagnostic biopsy materials, these efforts have 
not been successful, which is thought to be in part due to the variability in tissue penetration and delivery 
of these large proteins of ~150 kD10.
Because of difficulties in quantitating distribution and penetration of antibody-based therapeutics 
in human solid tumors, there is limited understanding of peri- and intratumoral delivery, and how 
this might impact patient response, together with local and systemic toxicity. In this study, we evalu-
ate, for the first time in humans, the distribution of intratumoral anti-EGFR antibody using cetuximab 
conjugated to the near-infrared fluorescent dye IRDye800CW (cetuximab-IRDye800CW), which does 
not alter the binding capacity of cetuximab, pharmacokinetics or biodistribution, as previously shown11. 
Correlating tumor and stromal characteristics with fluorescence labeled antibody delivery to the tumor 
may serve as an opportunity to provide additional information about predictors of clinical response and 
toxicity to therapeutic antibodies, but also to resistance patterns by labeling other effector proteins with 
different fluorescent wavelengths providing multispectral (NIR) antibody and effector imaging in situ. 
To this end, we evaluated systemically administered cetuximab-IRDye800CW and its in situ fluores-
cence as a correlate of antibody distribution in surgical resection specimens, in the context of a Phase I 
safety and toxicity trial in patients with HNSCC (Clinicaltrials.gov Identifier: NCT01987375). We tested 
the hypothesis that EGFR density, vascular density, and tumor proliferation are directly associated with 
tumor cetuximab-IRDye800CW fluorescence localization and intensity.
Results
There were a total of 9 patients with advanced squamous cell carcinoma arising in the head and neck 
that were systemically injected with cetuximab-IRDye800CW prior to curative surgical resection of their 
tumor. To confirm the integrity of the antibody-dye conjugate after systemic injection, SDS-PAGE of 
blood samples by imaging gels at the near infrared range demonstrates fluorescence bands at the expected 
molecular weight of 150kD while free, unbound dye could not be detected (Fig. 1a). A toxicology study 
performed in non-human primates has demonstrated that cetuximab-IRDye800CW has the same serum 
half-life as cetuximab (i.e. 2.5 days) and retains similar antigen binding specificity11. Our study demon-
strated the cetuximab-IRDye800CW serum half-life to be 1.2 days, 1.3 days and 1.6 days for the 2.5 mg/
m2, 25 mg/m2 and 62.5 mg/m2 doses, respectively. Surgical pathology specimens of the tumor and normal 
tissues were imaged using a closed field imaging system (Odyssey, LI-COR Biosciences) prior to histolog-
ical sectioning and the differential fluorescence measured (Fig. 1b). Cetuximab-IRDye800CW localized 
specifically in tumor regions, as confirmed by histology and cytokeratin immunohistochemistry. Analysis 
of the histological sections with equal thresh holding demonstrated that the mean fluorescence intensity 
(MFI) was significantly higher in SCC compared to corresponding adjacent tissues (P < 0.001) across all 
three dosing cohorts (Fig. 1c). The tumor-to-normal-ratio of cetuximab-IRDye800CW MFI was 2.2, 2.5, 
and 1.9 at 2.5 mg/m2, 25 mg/m2 and 62.5 mg/m2 doses, respectively. A 10-fold increase in single infusion 
dose (25 mg/m2 vs. 2.5 mg/m2) resulted in an almost 7-fold increase in MFI. Yet, further 25-fold increase 
in infusion dose (2.5 mg/m2 vs. 62.5 mg/m2) yielded only 8.8-fold increase in the MFI, with decreased 
tumor/normal ratio due to higher background (i.e. from 2.5 to 1.9).
Molecular correlates. Using fluorescence intensity as a readout for cetuximab-IRDye800CW accu-
mulation within the tissues, the MFI was correlated with biological characteristics of the tumor that 
might also influence antibody (peri-)tumoral distribution and binding into the tumor including cytoker-
atin (tumor density), EGFR expression, Factor VIII (vascular density) and Ki67 (proliferation) for each 
dose group (Table 1). Univariate analysis with respect to SCC demonstrated that tumor density, EGFR 
expression, and vascular density were directly associated with MFI (P < 0.05) in all three dosing cohorts, 
whereas Ki67 and MFI were significantly associated (P < 0.05) at the lowest dose concentration group 
(2.5 mg/m2). EGFR expression was independently associated with MFI, when adjusted for cytokeratin, 
Factor VIII and Ki67, at doses of 2.5 mg/m2 and 25 mg/m2, (P < 0.001).
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Figure 1. Localization of cetuximab-IRDye800CW in histologic sections of tissue with tonsil, tongue and 
cutaneous squamous cell carcinoma (SCC). (a) Representative 150 kD (=intact cetuximab-IRDye800CW) 
and 1kD (=IRDye800CW) bands are shown by SDS-PAGE of individual patient blood samples of each 
dosage cohort. (b) Representative haemotoxylin/eosin (H&E), cytokeratin and fluorescence image of 
SCC sections of tonsil, tongue and cutaneous origin. (c) Mean Fluorescence Intensity (MFI) quantified in 
pathology-positive areas of tumor and healthy surrounding for nine patients (n = 3 at each dosage cohort) 
for respectively 2.5 mg/m2, 25 mg/m2, and 62.5 mg/m2. Data are presented as mean ± SD, * = P < 0,001. Scale 
bars in all images represent 100 μm.
www.nature.com/scientificreports/
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EGFR fluorescence immunohistochemistry. Further analysis to correlate EGFR expression with 
MFI showed a strong correlation of squamous cell carcinoma (SCC) with EGFR expression (Fig.  2a). 
Clearly, cetuximab-IRDye800CW uptake within SCC was specifically localized to areas that expressed 
EGFR. The univariate association between EGFR density and MFI was observed at all three dosing 
cohorts (P < 0,001, Fig.  2b). A 6-fold increase in MFI was seen at the two higher doses compared to 
the lower dose concentration (P < 0,001); no significant increase in MFI was seen when comparing the 
highest dose (62.5 mg/m2) with the middle dose 25 mg/m2 (P > 0.05).
Fluorescence intensity correlates with distance to tumor. Representative H&E with tumor (T) 
and normal (N) are outlined in Fig. 3a and the corresponding tissue slide quantified in the fluorescence 
image (Fig. 3b). As demonstrated in Fig. 3c, a significant correlation between distance from tumor and 
signal-to-tumor ratio was shown (P < 0.001, P = 0.02 and P < 0.001; R square 0.996, 0.891 and 0.994 for 
the 2.5, 25 and 62.5 mg/m2 dosing cohorts, respectively) throughout all three dosing cohorts. A signif-
icant decrease in MFI (P < 0.001; 2.9, 2.4 and 2.1-fold reduction for the 2.5, 25 and 62.5 mg/m2 dosing 
cohorts, respectively) was shown at a distance of 1 mm from the tumor. Importantly, MFI significantly 
decreased when comparing the values between 5 mm and 1 mm from the tumor edge (P < 0.001; 8.3, 4.0 
and 6.3-fold reduction for the 2.5, 25 and 62.5 mg/m2 dosing cohorts, respectively).
Intratumoral cetuximab-resistant areas. Despite overall strong correlation between EGFR and 
SCC, there were discordant areas within tumors with high EGFR-expression that demonstrated low 
fluorescence. Histologically, these areas correspond to mature, differentiated keratinizing cancer cells 
that expressed moderate levels of EGFR, yet did not incorporate the antibody-dye conjugate (Fig.  4a). 
Comparing MFI of mature, differentiated keratinizing cancer cells to non-differentiated cancer area show 
enormous reduction in MFI, despite equal EGFR expression levels (Supplementary Fig. 1). Additionally, 
tumor necrosis was also clearly associated with areas of low fluorescence (Fig. 4b). Regression analysis 
collapsing the two groups with middle and highest doses (25 mg/m2 and 62.5 mg/m2) revealed an inverse 
relationship between cancer keratinization (Fig.  4c), and tumor necrosis (Fig.  4d) with MFI (P = 0.003 
and P < 0.001 respectively). SCC with ≥ 50% keratinization, or ≥ 50% necrosis demonstrated a larger than 
2-fold, and 1.7-fold decreased MFI.
Extratumoral in vivo fluorescence immunohistochemistry. EGFR is expressed in a wide range 
of normal tissues and anti-EGFR antibody targeting of these tissues influences the dose-dependent tox-
icities of therapy. In epidermal tissues, EGFR expression and corresponding cetuximab-IRDye800CW 
fluorescence was observed on the cell membrane of the basal cells and in the superficial cells under-
going terminal differentiation (Supplementary Fig. 2). Conversely, limited cetuximab-IRDye800CW 
uptake was observed in the more superficial differentiated epithelium. Sebaceous glands exhibited areas 





Square 95% CI P (n) 95% CI P
2.5 mg/m2 Cytokeratin 0.282 1.1 - 3.4 <0.001 (44) −0.5 - 2.3 0.211
EGFR-Density 0.526 1.6 - 3.1 <0.001 (40) 1.1 - 3.2 <0.001
Factor-VIII 0.090 −2.2 - 25.8 0.048 (32) −1.9 - 18.9 0.106
Ki67 0.158 0.1 - 0.3 0.007 (37) -0.2 - 0.1 0.435
25 mg/m2 Cytokeratin 0.217 5.1 - 19.1 <0.001 (46) -6.6 - 10.8 0.619
EGFR-Density 0.525 13.8 - 25.6 <0.001 (43) 8.6 - 26.7 <0.001
Factor-VIII 0.144 4.2 - 51.2 0.011 (36) −8.2 - 37.5 0.200
Ki67 0.027 −0.3 - 0.7 0.165 (37) −0.7 - 0.3 0.340
62.5 mg/m2 Cytokeratin 0.291 9.6 - 26.6 <0.001 (47) −7.1 - 24.4 0.255
EGFR-Density 0.422 9.0 - 20.9 <0.001 (38) −15.5 - 27.3 0.559
Factor-VIII 0.388 43.2 - 90.9 0.003 (28) −11.1 - 20.9 0.058
Ki67 0.058 −0.1 - 0.5 0.105 (29) −0.5 - 1.4 0.362
Table 1.  Mean Fluorescence intensity in univariate and multivariate analysis. The ratio of EGFR, Ki67, 
cytokeratin and factor VIII stained areas related to the total area of specimen. Uni- and multivariate 
regression analysis.
www.nature.com/scientificreports/
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Discussion
Although anti-EGFR therapies have been in clinical use for almost a decade in patients with squa-
mous cell carcinoma, there are no biomarkers that successfully predict patient response to treatment. 
Furthermore, there is minimal understanding of antibody penetration within the heterogeneous 
Figure 2. Co-localization of fluorescence signals of cetuximab-IRDye800CW and Epidermal Growth Factor 
Receptor (EGFR) expression. (a) Representative haemotoxylin/eosin (H&E) image indicating tumor (T) and 
normal (N) with corresponding EGFR expression immunohistochemistry stain and fluorescence image. (b) 
Increase in Mean Fluorescence Intensity (MFI) as a function of EGFR Density (% area EGFR positive). Data 
are presented as mean ± SD, * = P < 0,001. Scale bars in all images represent 100 μm.
www.nature.com/scientificreports/
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histological intratumoral and peritumoral compartments. In the first application of this technology in 
humans, we show that in vivo fluorescence immunohistochemistry (systemic injection of a near-infrared 
fluorescent monoclonal therapeutic antibody) can be used to localize cetuximab-IRDye800CW. This 
provided evidence that cetuximab delivery correlated with the expression of EGFR in almost all of the 
tumor tissues excised and provided significant insight into antibody compartmentalization not previously 
known or observable in humans. Interestingly, well-differentiated keratinizing tumor cells expressed high 
Figure 3. Fluorescence from adjacent normal tissue correlates with distance from tumor.Representative 
H&E image tumor (T) and normal (N) regions outlined by a board-certified pathologist (a). Signal-to-tumor 
ratio is determined at predefined distances from tumor (1-5 mm) as depicted by rectangular regions-of-
interest (ROI) at 0, 1, 2, 3, 4 and 5 mm margin distance (b) graphed (c). Data are presented as mean ± SD. 
Scale bar represent 50 μm.
www.nature.com/scientificreports/
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Figure 4. Effect of tissue properties on cetuximab-IRDye800CW uptake. (a) Representative haemotoxylin/
eosin (H&E) image and corresponding fluorescence image. Differentiated keratinizing cancer cells are 
outlined by black arrows. (b) White arrows outline tumor necrosis. (c) Regression analysis between % Area 
keratinized and Mean Fluorescence Intensity (MFI) (P < 0.003). (d) Regression analysis between % Area 
necrosis and Mean Fluorescence Intensity (MFI). Data are presented as mean ± SD, * = P < 0,001. Scale bars in 
all images represent 100 μm.
www.nature.com/scientificreports/
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levels of EGFR by immunohistochemistry, yet had significantly lower local fluorescence. This suggests 
that well-differentiated, keratinizing regions within squamous cell carcinomas may not be as effectively 
targeted with anti-EGFR therapies, although downstream effector proteins thought to be responsible for 
resistance, such as constitutive activation of STAT3, are not yet possible to track down in vivo. Other 
molecular markers that have been considered important for drug delivery and tumor penetration such as 
vascular density or tumor cell distribution surrounding (neo-)vasculature was not demonstrated in this 
cohort of nine patients and does not support the Enhanced Permeability and Retention (EPR) effect to 
be responsible for the distribution but more towards target-specific binding of cetuximab-IRDye800CW, 
as shown previously11.
Cetuximab-IRDye800CW specifically localized to SCC tumor cells arising in the head and neck and 
does not accumulate in non-epithelial tissues. Significantly higher mean fluorescent intensities (MFIs) 
were consistently noted within the carcinomas compared with normal tissues in all three dosing cohorts. 
When using a diagnostic dose of cetuximab, rather than repeated therapeutic delivery, higher cetuxi-
mab dosing may not correspond to greater cetuximab delivery in tumor tissues. Instead, more off-target 
uptake may be expected with less intratumoral uptake due to receptor saturation at the highest dose, as 
demonstrated using escalating doses of cetuximab-IRDye800CW.
We demonstrated that fluorescence was strongly correlated with the location of tumor and fell precip-
itously at a distance of 1 mm from the tumor edge (P < 0.001) in MFI intensity. This very sharp demarca-
tion between tumor and normal adjacent tissue was consistently measured throughout all three dosing 
cohorts. In vivo fluorescence immunohistochemistry could be used during frozen section analysis as a 
part of intraoperative fluorescence guided pathology, so that the surgeon could determine whether they 
are at an optimal distance.
We used in vivo fluorescence immunohistochemistry to provide insight into the mechanisms deter-
mining antibody delivery in SCC. To this end, we evaluated a number of biomarkers which are thought 
to modulate drug delivery or and peri- and intratumoral distribution. It was not surprising that fluo-
rescence intensity correlated significantly with EGFR expression density, since cetuximab-IRDye800CW 
accumulation depends upon EGFR expression as shown earlier11. However, earlier reports have men-
tioned that EGFR expression level is a poor predictor of response to cetuximab12. While we did not assess 
therapeutic response, we did observe that EGFR expression strongly correlated with overall fluorescence 
intensity, however, EGFR expression was associated with discordantly lower fluorescence intensity in 
regions of well-differentiated, keratinizing SCC.
We demonstrate that in tumor areas with ≥ 50% well differentiated tumors, these areas are associated 
with 2-fold decreased fluorescence compared with non-keratinizing foci within the same carcinoma. 
While reduced uptake in well-differentiated areas within the tumor could be attributed to reduced acces-
sibility or vascular permeability, the findings reported here are consistent with previous work demonstrat-
ing that EGFR loses ligand-binding affinity during maturation and differentiation13,14. We hypothesize 
that tumor maturation and keratinization contributes to decreased ligand affinity of EGFR or tissue 
penetration of the antibody, and may promote EGFR-inhibitor resistance. In addition, we also confirm 
tumor necrosis does not allow for cetuximab-IRDye800CW accumulation, which has also been recently 
noted by others in preclinical models15, and might be due to increased intratumoral pressure preventing 
influx of the cetuximab-IRDye800CW. For imaging and therapeutic purposes this might not be a limiting 
factor as the majority of vital tumor cells are situated around the periphery of tumor necrosis, which are 
of particular interest for image-guided surgery. Moreover, surgical margins are related to outgrowing vital 
tumor cells and not hypoxic, necrotic tumor cores.
Localization of our cetuximab-IRDye800CW bioconjugate in normal healthy tissues does explain 
some of the known toxicities associated with anti-EGFR therapy. Papulopustular eruption is an adverse 
reaction of the skin commonly seen in cancer patients treated with EGFR inhibitors16. The underlying 
mechanism, however, is still poorly defined. However, some have speculated that sebaceous glands might 
be the primary target of EGFR inhibitors and, as such, play a major role in the pathophysiology of papu-
lopustular eruption17. Consistent with this hypothesis, we have clearly demonstrated strong fluorescence 
intensity in sebaceous glands. These data support the hypothesis that papulopustular eruption results 
from accumulation of cetuximab as can be extrapolated from the data derived by the diagnostic agent 
cetuximab-IRDye800CW. Significant fluorescence levels were also found in the submandibular glands 
and sublingual glands, which showed the same intensity levels as vital tumor cells, suggesting signifi-
cant antibody targeting of the normal mucous glands. It is unclear if this results in clinically significant 
xerostomia since cetuximab is commonly given in conjunction with radiotherapy and as such the drug 
related toxicity is hard to differentiate from xerostomia caused by radiotherapy but very likely to result 
also by cetuximab off-site targeting.
Histological analysis of human tumors presented here suggests that the antibody-dye bioconjugate 
is highly specific for cancer cells and does not aspecifically accumulate within the stromal components 
of the tumor as might be the case when there is a profound EPR effect. The time interval between 
cetuximab-IRDye800CW and surgical resection was approximately 3–4 days, which provided suffi-
cient opportunity for the agent to circulate, as shown in both animal and human immunoPET and 
antibody-IRDye800CW studies18. Moreover, the shorter half-life of cetuximab-IRDye800CW (1.2 days, 
1.3 days and 1.6 days for the 2.5 mg/m2, 25 mg/m2 and 62.5 mg/m2 doses, respectively), compared to the 
original cetuximab helped to minimize background fluorescence signal.
www.nature.com/scientificreports/
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Conclusion
This is the first clinical study to evaluate peri- and intratumoral localization of an anti-EGFR fluores-
cently labeled antibody after systemic administration and denominated as in vivo fluorescence immuno-
histochemistry. Although EGFR expression correlated clearly with fluorescence intensity, further analysis 
of well-differentiated tumors with high levels of EGFR expression demonstrated near absent fluorescence 
suggesting poor uptake of the antibody in this histological subtype. As a spin-off of using therapeutic 
monoclonal antibodies as optical tracers in image-guided surgery, in vivo fluorescence immunohisto-
chemistry provides unsurpassed information of biodistribution and correlates with standard histopathol-
ogy which can be of great value in drug development of cancer immunotherapy Finally, this platform of 
using fluorescently labeled antibodies may be helpful to further elucidate effector proteins by multispec-
tral fluorescent in situ labeling.
Methods
Patients and patient tissue samples. Surgical resection specimens were collected from nine 
consented patients enrolled in a dose escalation (2.5 mg/m2, 25 mg/m2, and 62.5 mg/m2) clinical trial 
(Clinicaltrials.gov Identifier: NCT01987375) evaluating the safety and tumor-specificity of systemi-
cally injected cetuximab-IRDye800CW for surgical navigation in patients with HNSCC. As previously 
reported by us, IRDye800CW was conjugated to cetuximab at a molar ratio of (dye:protein) 2.3:111. Per 
trial design, patients received respective systemic intravenous infusion of cetuximab-IRDye800CW 3–4 
days prior to the scheduled surgical procedure. Pharmacokinetics assessments were performed prior 
to infusion and 2 hr, 24 hr, 3-4 days, 15 days and 30 days after study drug infusion. Aliquots of plasma 
samples (2.5 μL) were resolved by NuPAGE 4–12% Bis-Tris gel (Invitrogen Corporation; Carlsbad, CA). 
Mean fluorescence intensity (MFI) from size-matched regions of interest (ROIs) was recorded. A regres-
sion line was generated to determine plasma clearance of cetuximab-IRDye800CW. Informed consent 
was obtained from all patients and the University of Alabama Institutional Review Board approved the 
study. Patient data were anonymized and all experiments using the specimens were conducted in accord-
ance with the rules and regulations approved by the University of Alabama Institutional Review Board.
Fluorescence detection. Study patients received preoperative systemic intravenous infusions of 
cetuximab-IRDye800CW. As fluorescence is fairly undiminished by histological processing, fluorescence 
intensity remains measurable in the pathological specimens19. The fluorescence intensity of IRDye800CW 
was measured using unstained formalin fixed paraffin-embedded on glass slides sections (5 μm) of 
interest with a fluorescence flatbed scanner specifically designed for imaging IRDye800CW (Odyssey, 
LI-COR Biosciences); slides are left unstained to avoid interference with fluorescent measurements. MFI 
was measured within six regions of interest (ROIs) of squamous cell carcinoma (SCC) and also healthy 
surrounding tissue. Sodium dodecyl sulfate polyacrylamidegel electrophoresis (SDS-PAGE) was per-
formed on blood samples of the included patients at day 15 to ensure association between cetuximab 
and IRDye800CW as a complete cetuximab-IRDye800CW conjugation as described previously by us20.
Sample preparation and immunohistochemistry. Slides of interest were digitalized by whole 
slide scanning (Bioimagene, Ventana Medical Systems). Five μm sections were cut from respective 
formalin-fixed paraffin embedded specimens for fluorescence imaging, as stated above and immu-
nohistochemistry (IHC). IHC was performed to evaluate: EGFR (anti-human EGFR Ab-10, (1:100) 
Thermoscientific, Waltham, MA); density of carcinoma cells (anti-pan Cytokeratin Ab-961, (1:100) 
Abcam, Cambridge, MA); blood vessel density (anti-factor VIII-R, (1:100) Cellmarque, Rocklin, CA) and 
tumor proliferation (anti-Ki67 clone SP6, (1:100) Thermoscientific, Waltham, MA). Briefly, samples were 
de-paraffinized with EZ-DEWAX bath two times for 5 min. Antigen retrieval was achieved by heating for 
10 min at 100 °C then cooled at room temperature and blocked with 5% BSA (Bovine Serum Albumin) 
in TBS (Tris Buffered Saline) for 5 min at room temperature. Slides were incubated with the primary 
antibodies per manufacturer recommendations. Secondary antibody (goat anti-mouse, for EGFR and 
cytokeratin, and goat anti rabbit, for Ki67 and Factor VIII; 1:100) was applied for 1 h in a humidified 
chamber at room temperature. Peroxidase activity was visualized with 3,3-diaminobenzidine (DAB+) 
and mounted with mounting medium and coverslipped.
Analysis of Immunohistochemistry. Six regions ROIs from SCC and healthy surrounding tissue 
were selected. Staining intensities and distributions for Ki67, EGFR, cytokeratin and Factor VIII in each 
of the six ROIs were acquired using SPOT camera on an Olympus 1 × 70 microscope (Olympus Optical 
Co.), interfaced with a personal computer and SPOT software (Olympus Optical Co.). Positively stain-
ing areas were segmented by the signal intensity difference between the target cells and background in 
each photograph (x20), whereas the intensity and minimum particle size thresholds were set manually. 
Next, antigen stained cells were counted and the amount of cells per field of view (x20) reported. The 
ratio of EGFR, Ki67, cytokeratin and factor VIII stained areas related to the total area of specimen were 
calculated (EGFR-stained area/total area; Ki67-stained area/total area; cytokeratin-stained area/total area; 
factor VIII-stained area/total area) representing EGFR expression, cell proliferation, tumor and vascular 
density, respectively as described previously by us20. Image analysis was conducted by using ImageJ.
www.nature.com/scientificreports/
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Signal-to-tumor ratio for determination of margin distance to tumor. All tumor containing 
slides from each of the three dose groups were tested for the following inclusion criteria; i) tumor size of 
at least 5 mm, as determined by a board-certified pathologist, ii) intact tissue (i.e. no cuts, tears and mini-
mal presence of adipose fat tissue), and iii) normal adjacent tissue of at least 5 mm. A ROI (3 × 1 mm) was 
drawn at the tumor edge with subsequent ROIs placed 1 mm situated out of the previous region. Equal 
sized ROIs, distant from the tumor site, were used to calculate background fluorescence intensities for 
each patient and subsequently subtracted from the MFI determined from each ROI. The MFI of adjacent 
normal tissue (i.e. 1–5 mm) was divided by the MFI of the tumor edge to determine the signal-to-tumor 
ratio at the predefined distances.
Statistical analysis. Descriptive statistics were calculated for variables of interest. Statistical dif-
ferences between SCC, normal tissues in terms of MFI were tested separately at each of the three 
cetuximab-IRDye800CW dosage levels. Mixed modeling was performed using the lme2 package in R v 
3.0.1, adjusting for the number of repeated measurements per patient sample. Univariate and multivariate 
analysis was performed using SPSS 21.0 to separate out independent variables. Pearson correlation was 
performed to measure the strength of the linear relationships. Statistical significance was set at P ≤ 0.05.
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